1 0

    FDA Adverse Event Reports on DAYBUE (trofinetide) and Nuplazid (pimavanserin) from January 1, 2023

    FDA Adverse Event Reports on DAYBUE (trofinetide) and Nuplazid (pimavanserin) from January 1, 2023

    $89.00 USD
    $89.00 USD
    Sale Sold out
    Original Request: Please provide the full detailed adverse events reports on DAYBUE (trofinetide) and Nuplazid (pimavanserin). Time period: January 1, 2023 to date request is fulfilled. Thank you.
    Tags: Pharma, Adverse Event, 2023
    • Status: Pending Fast-Track Request
    • Delivery: Approximately 1 to 2 weeks when the FOIA office is operating at regular capacity

    NOTE: This document is not currently in our library. Upon purchase, we will request the document from the FDA FOIA office. Learn more about Fast-Track Requests here.

    View full details